These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27908315)

  • 1. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
    Lindberg MJ; Kristensen FB; Yildiz A
    Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
    Lee IH; Ahn DJ
    Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin-Associated Diabetic Ketoacidosis.
    Chakinala RC; Chang AP; Solanki S; Haq KF; Cho R
    Am J Ther; 2018; 25(6):e765-e766. PubMed ID: 29672334
    [No Abstract]   [Full Text] [Related]  

  • 4. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 7. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
    Ahmed M; McKenna MJ; Crowley RK
    Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors May Predispose to Ketoacidosis.
    Taylor SI; Blau JE; Rother KI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2849-52. PubMed ID: 26086329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
    Yeo SM; Park H; Paek JH; Park WY; Han S; Park SB; Jin K
    Medicine (Baltimore); 2019 Jan; 98(3):e14150. PubMed ID: 30653152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
    Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
    BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 12. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
    Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
    Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
    Chou YM; Seak CJ; Goh ZNL; Seak JC; Seak CK; Lin CC
    Medicine (Baltimore); 2018 Jun; 97(25):e11056. PubMed ID: 29923997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.
    Pfützner A; Klonoff D; Heinemann L; Ejskjaer N; Pickup J
    Endocrine; 2017 Apr; 56(1):212-216. PubMed ID: 28303514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
    Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
    Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
    Leader R; Cowen J; Rajeev SP
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.